β-卡博林类化合物的抗癌潜力:最新的机制概述
Phumudzo P Tshikhudo1, Tafadzwanashe Mabhaudhi2, Neil A Koorbanally3
1Department of Agriculture, Land Reform and Rural Development, Directorate Plant Health, Division Pest Risk Analysis, Arcadia, Pretoria, South Africa.
Chemistry & biodiversity
|December 18, 2023
概括
药用植物产生具有显著抗癌潜力的β-卡博林. 这些天然化合物在癌症治疗,管理和预防方面表现有前途,为癌症提供新的治疗途径.
科学领域:
- 药理学和天然产品化学化学
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 药用植物是生物活性化合物的丰富来源.
- β-卡博林是一种在各种植物中发现的类化合物.
- 它们在癌症治疗中的潜力需要全面评估.
研究的目的:
- 审查和评估来自药用植物的β-卡博林的抗癌性质.
- 评估它们对癌症治疗,管理和预防的适用性.
- 分析它们的抗癌机制.
主要方法:
- 进行了关于β-卡博林的详尽文献调查.
- 包括像harmaline,harmine和norharmane这样的化合物.
- 使用各种查技术分析了抗癌机制.
主要成果:
- 天然β-卡博林 (例如,harmaline,harmine) 在体外和体外显著抑制了癌细胞生长.
- 合成衍生的β-卡博林表现出抗癌,神经保护和认知增强作用.
- 多项研究支持这些化合物的抗癌疗效.
结论:
- β-卡博林是癌症治疗中生物活性化合物的有希望的来源.
- 药用植物衍生的β-卡博林为新的癌症治疗策略提供了宝贵的见解.
- 对β-卡博林的进一步研究可以促进癌症管理和预防.
更多相关视频
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K
Electron Transport Chain: Complex I and II
13.8K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.8K


